Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P01130: Variant p.Cys197Arg

Low-density lipoprotein receptor
Gene: LDLR
Feedback?
Variant information Variant position: help 197 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Cysteine (C) to Arginine (R) at position 197 (C197R, p.Cys197Arg). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and polar (C) to large size and basic (R) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In FHCL1. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 197 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 860 The length of the canonical sequence.
Location on the sequence: help SDEWPQRCRGLYVFQGDSSP C SAFEFHCLSGECIHSSWRCD The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         SDEWPQRCRGLYVFQ--GDSSPCSAFEFHCLSGECIHSSWRCD

Mouse                         SDEWPQNCQGRDTASK-GVSSPCSSLEFHCGSSECIHRSWV

Rat                           SDEWPQNCGAEDTAAE-VVSSPCSSLEFHCGSSECIHRSWV

Bovine                        SDEWPKHCGTPHPSGPLQDNNPCSALEFHCGSGECIHSSWH
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 22 – 860 Low-density lipoprotein receptor
Topological domain 22 – 788 Extracellular
Domain 195 – 233 LDL-receptor class A 5
Region 146 – 233 Binding to Getah virus E1-E2 spike glycoproteins
Disulfide bond 197 – 209
Alternative sequence 105 – 272 Missing. In isoform 3.
Alternative sequence 106 – 232 Missing. In isoform 2.
Mutagenesis 208 – 208 E -> R. Partial loss of binding to Getah virus E2-E1 spike glycoproteins.
Mutagenesis 214 – 214 W -> I. Partial loss of binding to Getah virus E2-E1 spike glycoproteins.
Mutagenesis 217 – 217 D -> K. Partial loss of binding to Getah virus E2-E1 spike glycoproteins.



Literature citations
Characterization of mutations in the low density lipoprotein (LDL)-receptor gene in patients with homozygous familial hypercholesterolemia, and frequency of these mutations in FH patients in the United Kingdom.
Webb J.C.; Sun X.-M.; McCarthy S.N.; Neuwirth C.; Thompson G.R.; Knigh B.; Soutar A.K.;
J. Lipid Res. 37:368-381(1996)
Cited for: VARIANTS FHCL1 ARG-197; TYR-248; ALA-301; TRP-302 AND PRO-350;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.